Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Potassium Channel>>Pinacidil monohydrate

Pinacidil monohydrate Sale

(Synonyms: 吡那地尔一水合物; P-1134 monohydrate) 目录号 : GC30267

A potassium channel opener

Pinacidil monohydrate Chemical Structure

Cas No.:85371-64-8

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥397.00
现货
5mg
¥360.00
现货
10mg
¥504.00
现货
25mg
¥1,060.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Pinacidil is a cyanoguanidine compound that acts as a potassium channel opener, activating the ATP-modulated potassium channels of guinea pig bladder and heart with Ki values of 104 and 251 nM, respectively.1,2,3 It completely relaxes coronary artery rings preconstricted with serotonin .4 Through this mechanism, pinacidil causes vascular relaxation, decreases peripheral vascular resistance, and reduces hypertension in animals and humans.5,6

1.Hermsmeyer, R.K.Pinacidil actions on ion channels in vascular muscleJ. Biomed. Sci.12(Suppl 2)S17-S22(1988) 2.Davis-Taber, R., Molinari, E.J., Altenbach, R.J., et al.[125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: Characterization and pharmacology of bindingMol. Pharmacol.64(1)143-153(2003) 3.Coghlan, M.J., Carroll, W.A., and Gopalakrishnan, M.Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progressJ. Med. Chem.44(11)1627-1653(2001) 4.Gollasch, M., Bychkov, R., Ried, C., et al.Pinacidil relaxes porcine and human coronary arteries by activating ATP-dependent potassium channels in smooth muscle cellsJ. Pharmacol. Exp. Ther.275(2)681-692(1995) 5.Cohen, M.L., and Kurz, K.D.Pinacidil-induced vascular relaxation: Comparison to other vasodilators and to classical mechanisms of vasodilationJ. Biomed. Sci.12(Suppl 2)S5-S9(1988) 6.Goldberg, M.R.Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channelsJ. Biomed. Sci.12(Suppl 2)S41-S47(1988)

Chemical Properties

Cas No. 85371-64-8 SDF
别名 吡那地尔一水合物; P-1134 monohydrate
Canonical SMILES [H]O[H].CC(C)(C)C(N/C(NC#N)=N/C1=CC=NC=C1)C
分子式 C13H21N5O 分子量 263.34
溶解度 50 mg/ml in Ethanol (Need ultrasonic); 50 mg/ml in DMSO (Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.7974 mL 18.9869 mL 37.9737 mL
5 mM 0.7595 mL 3.7974 mL 7.5947 mL
10 mM 0.3797 mL 1.8987 mL 3.7974 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Disposition of [14C]pinacidil in humans

Pinacidil [(+/-)-2-cyano-1-(4-pyridyl)-3-(1,2,2-trimethylpropyl)guanidine monohydrate] is a novel, direct-acting vasodilator antihypertensive agent. The cyano 14C-labeled drug is rapidly and completely absorbed after an oral 12.5-mg dose in solution. The blood:plasma concentration ratios (0.8-0.9) indicate transient penetration of radioactivity into blood cells. Blood and plasma tmax (0.5 h) and t 1/2 (4 h) of [14C]pinacidil equivalents are similar. Pinacidil (51%), pinacidil N-oxide (28%), and unidentified polar metabolites (21%) comprise the plasma radioactivity. The plasma t 1/2 of pinacidil is 2-3 h, and that of pinacidil N-oxide is 4-5 h. Renal excretion of radioactivity is the major route (80-90% dose) of drug elimination; fecal elimination accounted for 4% of the dose. Renal clearance of the N-oxide is 10 times the renal clearance of the parent drug and exceeds the creatinine clearance. Biotransformation products in 0-24-h urine samples include pinacidil (10%), pinacidil N-oxide (60%), and free and conjugated analogues of pinacidil and metabolites (30%). Stereoselective metabolism is not a major biotransformation pathway of pinacidil or the N-oxide metabolite.

In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note

The present work aimed to characterize transdermal drug delivery systems of pinacidil monohydrate in vivo by monitoring the effect of the TDDS on blood pressure of methyl prednisolone acetate induced hypertensive rats. The blood pressure of rats was measured using a noninvasive rat BP instrument based on cuff tail technique. A significant fall in rat BP (P<.01) was observed in treatment of hypertensive rats with all the formulations, which was maintained for 48 hours. Interformulation comparison revealed that formulation B-4 was the most effective with 37.96% reduction in BP (160.33±4.96 vs 99.44±4.46 mmHg). It was concluded that a single patch application of pinacidil TDDS (B-4) can effectively control hypertension in rats for 2 days. The system holds promise for clinical studies.

Monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: in vitro characterisation

The monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate (PM) were prepared by film casting technique on mercury substrate and characterised in vitro by drug release studies using paddle over disc assembly, skin permeation studies using Keshary and Chein diffusion cell on albino rat skin and drug-excipient interaction analysis. Four formulations were developed which differed in the ratio of matrix forming polymers, Eudragit RL-100 and PVP K-30, i.e. 8:2, 4:6, 2:8 and 6:4 and were coded as B-1, B-2, B-3 and B-4, respectively. All the four formulations carried 20% w/w of PM, 5% w/w of plasticiser, PEG-400 and 5% w/w of DMSO (based on total polymer weight) in isopropyl alcohol: dichloromethane (40:60) solvent system. Cumulative % of drug released in 48 h from the four formulations was 63.96, 55.95, 52.26 and 92.18%. The corresponding values for cumulative amount of drug permeated for the said formulations were 57.28, 50.35, 46.38 and 86.54%, respectively. On the basis of in vitro drug release and skin permeation performance, formulation B-4 was found to be better than the other three formulations and it was selected as the optimised formulation. The interaction studies carried out by comparing the results of assay, ultraviolet, infrared and TLC analyses for the pure drug, medicated and placebo formulations indicated no chemical interaction between the drug and excipients.

In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: A technical note

The present work aimed to characterize transdermal drug delivery systems of pinacidil monohydrate in vivo by monitoring the effect of the TDDS on blood pressure of methyl prednisolone acetate induced hypertensive rats. The blood pressure of rats was measured using a noninvasive rat BP instrument based on cuff tail technique. A significant fall in rat BP (P<.01) was observed in treatment of hypertensive rats with all the formulations, which was maintained for 48 hours. Interformulation comparison revealed that formulation B-4 was the most effective with 37.96% reduction in BP (160.33±4.96 vs 99.44±4.46 mmHg). It was concluded that a single patch application of pinacidil TDDS (B-4) can effectively control hypertension in rats for 2 days. The system holds promise for clinical studies.

Postjunctional effect of pinacidil on contractility of isolated bovine trachealis

Potassium channel openers hyperpolarize the smooth muscle cell membrane and relax airway smooth muscle. In this study, pre- and postjunctional effects of pinacidil ((+/-) N-cyano-N'-(4-pyridil)-N"-(1,2,2-trimethylpropyl)-guanidine monohydrated), an adenosine triphosphate (ATP)-sensitive K(+)-channel opener, were determined in isolated bovine trachealis. The effects of pinacidil on the frequency-response to electrical field stimulation (EFS), 0.1-32 Hz, and on the concentration response to acetylcholine (ACh), 10(9)-10(-4) M, were compared in muscle strips from six animals. In addition, the effect of pinacidil on the inhibitory nonadrenergic noncholinergic (iNANC) system was evaluated in histamine-contracted muscle strips from another eight animals. Pinacidil (10(-6) or 10(-5) M) shifted both the EFS frequency-response and the ACh concentration-response curves significantly (p < 0.01) to the right. Glibenclamide (10(-7)-10(-5) M) antagonized these responses in a concentration-dependent manner. The inhibitory effects of pinacidil on contractions of the same magnitude induced by EFS or exogenous ACh were not significantly different (p = 0.11), suggesting that pinacidil had only a postjunctional effect. Pinacidil had no effect on iNANC-mediated muscle relaxation. We conclude that pinacidil attenuates the contraction of isolated bovine tracheal smooth muscle by postjunctional mechanisms.